

AMRN, Initiating as an Outperform - ANCHORING a Foot hold in the Dyslipidemia Market

<https://marketpublishers.com/r/ABAC55597F3EN.html>

Date: July 2011

Pages: 8

Price: US\$ 140.00 (Single User License)

ID: ABAC55597F3EN

Abstracts

Amarin Corp. (AMRN)'s lead product AMR101 (omega fatty acid – no DHA) has blockbuster potential being the best-in-class drug vs. approved drugs to treat hypertriglyceridemia. AMRN intends to file the NDA for hypertriglyceridemia – (TG level: >500 mg/dL) in 3Q11 and other indications next year. We expect partnership/acquisition by For more detail, please read our report released on July 5, 2011, titled – “ANCHORING a Foot hold in the Dyslipidemia Market”.

Contents

COMPANIES MENTIONED

Amarin Corporation

I would like to order

Product name: AMRN, Initiating as an Outperform - ANCHORING a Foot hold in the Dyslipidemia Market

Product link: <https://marketpublishers.com/r/ABAC55597F3EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ABAC55597F3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970